Odyssey Therapeutics Secures $25M Private Placement Concurrent with IPO
Summary
Odyssey Therapeutics completed a $25 million private placement with TPG at its IPO price, bolstering its capital position as it transitions to a public company.
Key Events
-
Private Placement Completed
Odyssey Therapeutics sold 1,388,889 shares of common stock to TPG LSI Rise Orazio II, L.P., an affiliate of an existing stockholder, for a total of $25,000,002.
-
Pricing at IPO Level
The shares were sold at $18.00 per share, matching the initial public offering price and representing a premium to the current market price of $17.45.
-
Concurrent with IPO
The private placement closed concurrently with the company's initial public offering, providing additional capital as the company went public.
-
Corporate Governance Established
The company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, effective May 11, 2026, in connection with its IPO.
Analysis
This filing details a significant $25 million private placement of common stock to an affiliate of an existing institutional stockholder, TPG, at the initial public offering price of $18.00 per share. This transaction closed concurrently with the company's IPO, providing additional capital and demonstrating strong institutional support for the newly public entity. The private placement price is also at a premium to the current market price of $17.45. The filing also includes standard amendments to the company's corporate charter and bylaws, establishing the governance framework for a public company.
At the time of this filing, ODTX was trading at $17.45 on NASDAQ in the Life Sciences sector. The 52-week trading range was $16.41 to $17.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.